On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target. In an investor note, the analyst cited ...

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting ...

Corcept Therapeutics is rated hold due to high binary risk from an imminent Teva lawsuit decision impacting Korlym sales. Exceptional Phase 3 data for relacorilant in platinum-resistant ovarian cancer ...

Crooked frets, designed to solve the instrument’s biggest intonation issues, have won over some big-name players (even if ...

Corcept Therapeutics' (CORT) Relacorilant is currently under FDA review with a PDUFA target date of December 30, 2025. This upcoming regulatory milestone is financially pivotal for Corcept to reduce ...

An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Dr. Melody Bell is a personal finance expert, entrepreneur, educator, and researcher. Melody now develops ...

You’d be hard-pressed to find a true cinephile who doesn’t own a copy of Harold and Maude. The 1971 box office failure, directed by Hal Ashby and written by Colin Higgins, has become a Hollywood ...

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe ...

ST. LOUIS—A former congressional candidate who until recently was an assistant U.S. Attorney for the Eastern District of Missouri is St. Louis County Executive Sam Page’s choice to become the next ...